UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Recommendations for the diagnosis and treatment of the acute porphyrias

Annals of internal medicine, 2005-03, Vol.142 (6), p.439

2005

Volltextzugriff (PDF)

Tu1034 Undetectable HCV RNA Levels at Treatment Week 4 (TW4) With Sofosbuvir (SOF) and Simeprevir (SMV) for Genotype 1 Hepatitis C Virus May Predict Sustained Virologic Response at 12 Weeks After Treatment (SVR12): Results From an Academic Veterans Healthcare Center

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-1090-S-1091

2015

Volltextzugriff (PDF)

Proactive Case Finding to Improve Curative and Palliative Care Concurrently in Patients with End Stage Liver Disease (ESLD): A Quality Improvement Project (S769)

Journal of pain and symptom management, 2014-02, Vol.47 (2), p.508-508

2014

Volltextzugriff (PDF)

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

The New England journal of medicine, 2015-12, Vol.373 (27), p.2608-2617

2015

Volltextzugriff (PDF)

"Wait-and-see": an alternative approach to managing acute hepatitis C with high-dose interferon-alpha monotherapy

Annals of internal medicine, 2004-09, Vol.141 (6), p.W91

2004

Volltextzugriff (PDF)

Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C

Digestive diseases and sciences, 2004-06, Vol.49 (6), p.1000-1006

2004

Volltextzugriff (PDF)

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C

Hepatology (Baltimore, Md.), 1998-11, Vol.28 (5), p.1411-1415

1998

Volltextzugriff (PDF)

Proactive case finding to improve concurrently curative and palliative care in patients with end-stage liver disease

Journal of palliative medicine, 2015-04, Vol.18 (4), p.378

2015

Volltextzugriff (PDF)

Abstract 3247: SAMe versus placebo for the reduction of serum AFP in patients with hepatitis C cirrhosis and moderately elevated AFP: A randomized, placebo-controlled, double-blind phase II trial

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3247-3247

2014

Volltextzugriff (PDF)

Cryptogenic Ascites from Biopsy Proven Coccidiomycosis in a Seronegative Immunosuppressed Solid Organ Transplant Patient: 953

The American journal of gastroenterology, 2012-10, Vol.107, p.S389

2012

Volltextzugriff (PDF)

A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP

Cancer prevention research (Philadelphia, Pa.), 2015-09, Vol.8 (9), p.864-872

2015

Volltextzugriff (PDF)

Roles and pitfalls of transplantation in human porphyria

Liver transplantation, 2005-12, Vol.11 (12), p.1460-1462

Pimstone, Neville Roy

2005

Volltextzugriff (PDF)

Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america

Hepatology (Baltimore, Md.), 1998-06, Vol.27 (6), p.1661-1669

1998

Volltextzugriff (PDF)

Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration

The American journal of gastroenterology, 1999-12, Vol.94 (12), p.3583-3588

1999

Volltextzugriff (PDF)

Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria

The New England journal of medicine, 1987-02, Vol.316 (7), p.390

1987

Volltextzugriff (PDF)

Evaluation of hepatocellular function by way of receptor‐mediated uptake of a technetium‐99m—labeled asialoglycoprotein analog

Hepatology (Baltimore, Md.), 1994-10, Vol.20 (4), p.917-923

1994

Volltextzugriff (PDF)

Early Hepatitis C virus–RNA responses predict interferon treatment outcomes in chronic hepatitis C

Hepatology (Baltimore, Md.), 1998-11, Vol.28 (5), p.1411-1415

1998

Volltextzugriff (PDF)

Free radical mechanism of oxidation of uroporphyrinogen in the presence of ferrous iron

Archives of biochemistry and biophysics, 1990-09, Vol.281 (2), p.177-184

1990

Volltextzugriff (PDF)

Selective in vivo tumor localization of uroporphyrin isomer I in mouse mammary carcinoma: superiority over other porphyrins in a comparative study

Cancer research (Chicago, Ill.), 1986-09, Vol.46 (9), p.4390-4394

1986

Volltextzugriff (PDF)

Porphyria Cutanea Tarda

Seminars in liver disease, 1982-05, Vol.2 (2), p.132-142

Pimstone, Neville R.

1982

Volltextzugriff (PDF)

Ribavirin/interferon alpha-2b therapy is very effective in the treatment of chronic hepatitis C genotype 2 & 3 patients who have failed to respond virologically to interferon monotherapy

Journal of hepatology, 2002-04, Vol.36, p.129-129

2002

Volltextzugriff (PDF)

Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C

The American journal of gastroenterology, 2002-09, Vol.97 (9), p.S65-S65

2002

Volltextzugriff (PDF)

High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for acute hepatitis C

Gastroenterology (New York, N.Y. 1943), 2000-04, Vol.118 (4), p.A960-A960

2000

Volltextzugriff (PDF)

Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration

The American journal of gastroenterology, 1999-12, Vol.94 (12), p.3583-3588

1999

Volltextzugriff (PDF)

Acute renal failure associated with nonfulminant hepatitis A viral infection

The American journal of gastroenterology, 1996-02, Vol.91 (2), p.369-372

1996

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Recommendations for the diagnosis and treatment of the acute porphyrias

Tu1034 Undetectable HCV RNA Levels at Treatment Week 4 (TW4) With Sofosbuvir (SOF) and Simeprevir (SMV) for Genotype 1 Hepatitis C Virus May Predict Sustained Virologic Response at 12 Weeks After Treatment (SVR12): Results From an Academic Veterans Healthcare Center

Proactive Case Finding to Improve Curative and Palliative Care Concurrently in Patients with End Stage Liver Disease (ESLD): A Quality Improvement Project (S769)

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

"Wait-and-see": an alternative approach to managing acute hepatitis C with high-dose interferon-alpha monotherapy

Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C

Proactive case finding to improve concurrently curative and palliative care in patients with end-stage liver disease

Abstract 3247: SAMe versus placebo for the reduction of serum AFP in patients with hepatitis C cirrhosis and moderately elevated AFP: A randomized, placebo-controlled, double-blind phase II trial

Cryptogenic Ascites from Biopsy Proven Coccidiomycosis in a Seronegative Immunosuppressed Solid Organ Transplant Patient: 953

A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP

Roles and pitfalls of transplantation in human porphyria

Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america

Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration

Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria

Evaluation of hepatocellular function by way of receptor‐mediated uptake of a technetium‐99m—labeled asialoglycoprotein analog

Early Hepatitis C virus–RNA responses predict interferon treatment outcomes in chronic hepatitis C

Free radical mechanism of oxidation of uroporphyrinogen in the presence of ferrous iron

Selective in vivo tumor localization of uroporphyrin isomer I in mouse mammary carcinoma: superiority over other porphyrins in a comparative study

Porphyria Cutanea Tarda

Ribavirin/interferon alpha-2b therapy is very effective in the treatment of chronic hepatitis C genotype 2 & 3 patients who have failed to respond virologically to interferon monotherapy

Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C

High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for acute hepatitis C

Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration

Acute renal failure associated with nonfulminant hepatitis A viral infection

Suchergebnisse filtern